Ventiv Health, a US provider of marketing and sales solutions to the pharmaceutical and life sciences industries, says that it has successfully completed the acquisition of Franklin Group. The financial terms of the transaction were not disclosed.
Ventiv chief executive Eran Broshy noted that "Franklin is a recognized leader in the rapidly growing US market for pharmaceutical compliance services and patient assistance programs, and currently provides services to a majority of the top-ranked global pharmaceutical companies. The combination of Ventiv and Franklin establishes an expanded suite of offerings with an unprecedented level of integrated compliance oversight embedded into these services. It also provides new opportunities for growth and supports our goal of providing full-service programs to companies in the pharmaceutical and biotechnology areas. We expect Franklin's operations to be immediately accretive to Ventiv's earnings per share."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze